Characterisation of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO, or IPI alone Meeting Abstract

  

Authors:	Robert, C.; Larkin, J.; Ascierto, P. A.; Long, G. V.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbe, C.; Grob, J. J.; Grossmann, K.; Wagstaff, J.; Chesney, J.; Hogg, D.; Bechter, O.; Marquez-Rodas, I.; Pavlick, A. C.; Walker, D.; Bhore, R.; Postow, M. A.; Wolchok, J. D.
Abstract Title:	Characterisation of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO, or IPI alone
Meeting Title:	COSA's 44th Annual Scientific Meeting
Journal Title:	Asia-Pacific Journal of Clinical Oncology
Volume:	13
Issue:	Suppl. 4
Meeting Dates:	2017 Nov 13-15
Meeting Location:	Sydney, Australia
ISSN:	1743-7555
Publisher:	Wiley Blackwell
Date Published:	2017-11-01
Start Page:	136
End Page:	137
Language:	English
ACCESSION:	WOS:000413954500193
PROVIDER:	wos
PUBMED:	29082610
DOI:	10.1111/ajco.12799
Notes:	Meeting Abstract: 200 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/118373